Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | PAM | P19021 | 2/20 | 0.57 |
| ▸ | NAAA | Q02083 | 2/20 | 0.57 |
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8542334 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL128518 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL78918 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL9003221 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL1047634 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL18585990 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL11227533 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| Hexane SCHEMBL15129396 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL4457033 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 | |
| SCHEMBL8859535 | 1.00 | DGKA (0.64) | DGKALMNAPAMNAAACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7033614-B2 | Bismuth oxychloride compositions and methods of rinsing | EMD CHEMICALS, INC. (PREVIOUSLY EM INDUSTRIES) (US) | 2006-04-25 | — | — | US | claimed |
| US-20050048014-A1 | Bismuth oxychloride compositions and methods of rinsing | EM INDUSTRIES (US) | 2005-03-03 | — | — | US | claimed |
| US-5567420-A | SUCH AS SUNSCREEN AGENT | GE CANADA FINANCE HOLDING COMPANY (CA) | 1996-10-22 | — | — | US | claimed |
| WO-1996014826-A1 | LOTION WHICH IS TEMPORARILY COLORED UPON APPLICATION | SEEUV (US) | 1996-05-23 | — | — | WO | claimed |
| EP-3886791-B1 | CLAY MASK COMPOSITION AND METHOD FOR USING THE SAME | UNILEVER GLOBAL IP LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-4601699-A1 | LIPID NANOPARTICLE FORMULATIONS FOR MRNA DELIVERY TO LANGERHANS CELLS | Cutanos GmbH (AT) | 2025-08-20 | — | — | EP | disclosed |
| EP-3740242-B1 | LANGERIN+-CELL TARGETING | MAX PLANCK GESELLSCHAFT (DE) | 2025-06-18 | — | — | EP | disclosed |
| US-12290535-B2 | Langerin+ cell targeting | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-05-06 | — | — | US | disclosed |
| WO-2024079352-A1 | LIPID NANOPARTICLE FORMULATIONS FOR MRNA DELIVERY TO LANGERHANS CELLS | CUTANOS GMBH (AT) | 2024-04-18 | — | — | WO | disclosed |
| US-20220080004-A1 | Microorganisms Inhibiting the Formation of Axillary Malodor | BASF SE (DE) | 2022-03-17 | — | — | US | disclosed |
| US-20220079871-A1 | MICROORGANISMS INHIBITING THE FORMATION OF FOOT MALODOR | BASF SE (DE) | 2022-03-17 | — | — | US | disclosed |
| US-10953051-B2 | Methods and means for protecting the skin against pathogenic microorganisms | NOVOZYMES A/S (DK) | 2021-03-23 | — | — | US | disclosed |
| US-5417674-A | Separately packaged applicator pads for topical delivery of incompatible drugs | CREATIVE PRODUCTS RESOURCE ASSOCIATES, LTD. (US) | 1995-05-23 | — | — | US | disclosed |
| US-5368581-A | Method of using a packaging system with folded applicator pads for topical drug delivery | CREATIVE PRODUCTS RESOURCE ASSOCIATES, LTD. (US) | 1994-11-29 | — | — | US | disclosed |
| WO-1994013354-A1 | IN-TANDEM APPLICATOR PADS FOR THERAPEUTIC AGENTS | CREATIVE PRODUCTS RESOURCE, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1994013353-A1 | SEPARATELY PACKAGED PADS FOR TOPICAL DRUG DELIVERY | CREATIVE PRODUCTS RESOURCE ASSOCIATES, LTD. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5254109-A | Separately packaged applicator pads for topical delivery of incompatable drugs | CREATIVE PRODUCTS RESOURCE ASSOCIATES, LTD. (US) | 1993-10-19 | — | — | US | disclosed |
| US-5242433-A | Packaging system with in-tandem applicator pads for topical drug delivery | CREATIVE PRODUCTS RESOURCE ASSOCIATES, LTD. (US) | 1993-09-07 | — | — | US | disclosed |
| WO-1991007168-A1 | RIBOFLAVIN AS A TANNING ENHANCER | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991007167-A1 | PROTEIN KINASE ACTIVATORS AS ENHANCERS OF MELANIN PRODUCTION | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12290535-B2 | Langerin+ cell targeting | CD209, CLEC4M, CD74 | DGKA 1160/4885LMNA 2520/4885PAM 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.